IMAX

IMAX Corporation NYSE

Communication Services ·Entertainment ·CA · imax.com

$36.51

After hrs $35.24 +0.00%

Mkt Cap $2.0B

52w Low $22.54 67.7% of range 52w High $43.16

50d MA $38.17 200d MA $34.08

P/E (TTM) 56.2x

EV/EBITDA 16.0x

P/B 4.6x

Debt/Equity 0.9x

ROE 10.3%

P/FCF 16.7x

RSI (14) —

ATR (14) —

Beta 0.40

50d MA $38.17

200d MA $34.08

Avg Volume 1.1M

About

IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company worldwide. It offers cinematic solution through proprietary software, theater architecture, intellectual property, and specialized equipment. The company offers IMAX Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 30, 2026	AMC	0.15	0.17	+13.3%	38.02	-6.6%	-4.0%	—	—	—	—	—	—
Feb 25, 2026	AMC	0.43	0.58	+34.9%	36.52	+4.0%	+14.4%	+17.3%	+15.1%	+12.8%	+12.7%	+0.1%	—
Oct 23, 2025	AMC	0.35	0.47	+34.1%	32.44	+0.4%	-2.3%	-0.7%	+1.0%	+1.4%	-0.0%	+11.0%	—
Jul 24, 2025	AMC	0.19	0.26	+36.8%	28.29	+1.0%	-5.1%	-4.7%	-8.1%	-9.3%	-8.8%	-2.2%	—
Apr 23, 2025	AMC	0.11	0.13	+18.2%	24.09	+3.8%	-3.3%	-0.8%	-0.5%	+1.3%	+1.0%	+12.0%	—
Feb 19, 2025	AMC	0.29	0.27	-6.9%	27.22	-1.7%	-1.1%	-4.4%	-3.5%	-3.0%	-5.5%	-1.7%	—
Oct 30, 2024	AMC	0.22	0.35	+59.1%	21.68	+1.5%	+12.1%	+11.0%	+11.6%	+11.9%	+14.1%	+21.4%	—
Jul 25, 2024	AMC	0.06	0.18	+200.0%	19.40	+2.3%	+3.6%	+2.5%	+6.4%	+8.8%	+9.2%	+13.1%	—
Apr 25, 2024	AMC	0.10	0.15	+50.0%	17.46	-0.2%	-1.8%	-2.2%	-8.3%	-7.3%	-6.2%	-6.4%	—
Feb 27, 2024	AMC	0.10	0.17	+70.0%	15.79	+7.3%	+11.1%	+8.5%	+6.8%	+5.6%	+7.4%	+2.4%	—
Oct 25, 2023	AMC	0.21	0.35	+66.7%	18.11	+1.2%	+0.7%	-0.9%	+0.6%	+0.6%	-0.1%	-8.2%	—
Jul 26, 2023	AMC	0.17	0.26	+52.9%	17.38	+13.7%	+8.5%	+7.2%	+5.9%	+5.9%	+7.1%	+7.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Macquarie	Maintains	Outperform → Outperform	—	$38.02	$35.52	-6.6%	-4.0%	—	—	—	—
May 1	Barrington Research	Maintains	Outperform → Outperform	—	$38.02	$35.52	-6.6%	-4.0%	—	—	—	—
May 1	JP Morgan	Maintains	Overweight → Overweight	—	$38.02	$35.52	-6.6%	-4.0%	—	—	—	—
Apr 23	Wedbush	Maintains	Outperform → Outperform	—	$36.22	$36.05	-0.5%	+1.1%	+0.6%	+2.5%	+2.1%	+2.8%
Apr 20	Rosenblatt	Maintains	Buy → Buy	—	$35.09	$35.00	-0.3%	+2.5%	+1.9%	+3.2%	+4.3%	+3.9%
Apr 8	Seaport Global	Maintains	Buy → Buy	—	$38.80	$39.67	+2.2%	-1.5%	-2.4%	-2.5%	-4.8%	-5.1%
Mar 2	Goldman Sachs	Maintains	Neutral → Neutral	—	$42.83	$42.58	-0.6%	-1.9%	-3.8%	-3.9%	-5.5%	-4.7%
Feb 26	Benchmark	Maintains	Buy → Buy	—	$36.52	$37.98	+4.0%	+14.4%	+17.3%	+15.1%	+12.8%	+12.7%
Feb 26	Macquarie	Maintains	Outperform → Outperform	—	$36.52	$37.98	+4.0%	+14.4%	+17.3%	+15.1%	+12.8%	+12.7%
Feb 26	Rosenblatt	Maintains	Buy → Buy	—	$36.52	$37.98	+4.0%	+14.4%	+17.3%	+15.1%	+12.8%	+12.7%
Feb 26	JP Morgan	Maintains	Overweight → Overweight	—	$36.52	$37.98	+4.0%	+14.4%	+17.3%	+15.1%	+12.8%	+12.7%
Feb 24	Rosenblatt	Maintains	Buy → Buy	—	$36.79	$36.76	-0.1%	+0.1%	-0.7%	+13.5%	+16.4%	+14.2%
Feb 23	Wedbush	Maintains	Outperform → Outperform	—	$37.81	$37.93	+0.3%	-2.7%	-2.6%	-3.4%	+10.5%	+13.3%
Jan 26	Barrington Research	Maintains	Outperform → Outperform	—	$34.61	$34.85	+0.7%	+0.4%	+0.4%	-0.3%	-0.7%	+0.9%
Jan 15	Macquarie	Maintains	Outperform → Outperform	—	$35.07	$35.11	+0.1%	+3.5%	+6.7%	+7.2%	+4.5%	+0.9%
Dec 18	Wells Fargo	Maintains	Overweight → Overweight	—	$37.42	$38.00	+1.6%	+0.1%	-0.3%	-0.3%	+0.1%	+0.8%
Dec 15	JP Morgan	Upgrade	Neutral → Overweight	—	$38.17	$39.28	+2.9%	+2.3%	-1.0%	-2.0%	-1.8%	-2.3%
Dec 8	Barrington Research	Maintains	Outperform → Outperform	—	$35.71	$36.42	+2.0%	+7.8%	+6.6%	+6.7%	+7.3%	+6.9%
Dec 8	Benchmark	Maintains	Buy → Buy	—	$35.71	$36.42	+2.0%	+7.8%	+6.6%	+6.7%	+7.3%	+6.9%
Dec 8	Wedbush	Maintains	Outperform → Outperform	—	$35.71	$36.42	+2.0%	+7.8%	+6.6%	+6.7%	+7.3%	+6.9%
Dec 8	Rosenblatt	Maintains	Buy → Buy	—	$35.71	$36.42	+2.0%	+7.8%	+6.6%	+6.7%	+7.3%	+6.9%
Nov 25	Goldman Sachs	Upgrade	Sell → Neutral	—	$36.00	$36.52	+1.4%	+0.1%	+2.4%	+3.1%	+2.3%	-1.1%
Oct 24	Barrington Research	Maintains	Outperform → Outperform	—	$32.44	$32.56	+0.4%	-2.3%	-0.7%	+1.0%	+1.4%	-0.0%
Oct 24	Wells Fargo	Maintains	Overweight → Overweight	—	$32.44	$32.56	+0.4%	-2.3%	-0.7%	+1.0%	+1.4%	-0.0%
Oct 24	Rosenblatt	Maintains	Buy → Buy	—	$32.44	$32.56	+0.4%	-2.3%	-0.7%	+1.0%	+1.4%	-0.0%
Oct 24	JP Morgan	Maintains	Neutral → Neutral	—	$32.44	$32.56	+0.4%	-2.3%	-0.7%	+1.0%	+1.4%	-0.0%
Oct 23	Barrington Research	Maintains	Outperform → Outperform	—	$32.06	$32.63	+1.8%	+1.2%	-1.1%	+0.5%	+2.2%	+2.7%
Oct 14	Roth Capital	Maintains	Buy → Buy	—	$31.09	$31.14	+0.2%	+0.7%	+2.0%	+1.5%	+3.7%	+4.3%
Oct 9	JP Morgan	Maintains	Neutral → Neutral	—	$32.22	$32.35	+0.4%	-1.1%	-3.2%	-3.5%	-2.9%	-1.6%
Oct 9	Rosenblatt	Maintains	Buy → Buy	—	$32.22	$32.35	+0.4%	-1.1%	-3.2%	-3.5%	-2.9%	-1.6%
Sep 23	Barrington Research	Maintains	Outperform → Outperform	—	$32.66	$32.71	+0.2%	-0.1%	-1.2%	-0.8%	-0.2%	-0.9%
Sep 22	Wedbush	Maintains	Outperform → Outperform	—	$31.96	$32.09	+0.4%	+2.2%	+2.1%	+1.0%	+1.4%	+2.0%
Sep 19	Barrington Research	Maintains	Outperform → Outperform	—	$32.31	$32.31	+0.0%	-1.1%	+1.1%	+1.0%	-0.1%	+0.3%
Jul 25	Benchmark	Maintains	Buy → Buy	—	$28.29	$28.57	+1.0%	-5.1%	-4.7%	-8.1%	-9.3%	-8.8%
Jul 25	Wells Fargo	Maintains	Overweight → Overweight	—	$28.29	$28.57	+1.0%	-5.1%	-4.7%	-8.1%	-9.3%	-8.8%
Jul 25	Wedbush	Maintains	Outperform → Outperform	—	$28.29	$28.57	+1.0%	-5.1%	-4.7%	-8.1%	-9.3%	-8.8%
Jul 25	Rosenblatt	Maintains	Buy → Buy	—	$28.29	$28.57	+1.0%	-5.1%	-4.7%	-8.1%	-9.3%	-8.8%
Jul 24	Barrington Research	Maintains	Outperform → Outperform	—	$29.03	$29.13	+0.3%	-2.5%	-7.5%	-7.1%	-10.5%	-11.6%
Jul 11	Rosenblatt	Maintains	Buy → Buy	—	$26.17	$26.40	+0.9%	+2.9%	+6.6%	+6.5%	+8.1%	+9.1%
Jul 9	Roth Capital	Maintains	Buy → Buy	—	$26.90	$26.78	-0.4%	-2.2%	-2.7%	+0.1%	+3.7%	+3.6%
Jun 16	Rosenblatt	Maintains	Buy → Buy	—	$28.88	$28.90	+0.1%	+1.2%	+1.0%	+1.1%	-1.5%	-3.7%
Jun 13	Roth Capital	Maintains	Buy → Buy	—	$28.60	$28.49	-0.4%	+1.0%	+2.2%	+2.0%	+2.1%	-0.6%
Apr 25	Macquarie	Maintains	Outperform → Outperform	—	$23.29	$22.81	-2.1%	+2.6%	+2.9%	+4.8%	+4.5%	+3.7%
Apr 24	Barrington Research	Maintains	Outperform → Outperform	—	$24.09	$25.00	+3.8%	-3.3%	-0.8%	-0.5%	+1.3%	+1.0%
Apr 24	Wells Fargo	Maintains	Overweight → Overweight	—	$24.09	$25.00	+3.8%	-3.3%	-0.8%	-0.5%	+1.3%	+1.0%
Apr 24	Rosenblatt	Maintains	Buy → Buy	—	$24.09	$25.00	+3.8%	-3.3%	-0.8%	-0.5%	+1.3%	+1.0%
Apr 11	JP Morgan	Maintains	Neutral → Neutral	—	$22.03	$22.09	+0.3%	-2.7%	-1.8%	-1.7%	-1.2%	+1.9%
Apr 10	Benchmark	Maintains	Buy → Buy	—	$23.44	$22.60	-3.6%	-6.0%	-8.5%	-7.7%	-7.6%	-7.1%
Apr 10	Rosenblatt	Maintains	Buy → Buy	—	$23.44	$22.60	-3.6%	-6.0%	-8.5%	-7.7%	-7.6%	-7.1%
Feb 21	JP Morgan	Maintains	Neutral → Neutral	—	$26.93	$27.20	+1.0%	-3.3%	-2.5%	-2.0%	-4.5%	-5.9%

Recent Filings

8-K · 5.02 !!! Very High

Unknown — 8-K Item 5.02: Executive Change

IMAX announced an executive change, which could signal leadership transition or strategy shifts; investors should monitor earnings guidance and operational continuity statements in follow-up disclosures.

Apr 17

8-K · 5.02 !!! Very High

Imax Corp -- 8-K 5.02: Executive Change

Robert D. Lister's appointment as interim principal executive officer at IMAX signals potential leadership transition uncertainty, likely prompting investor scrutiny of strategic direction and operational continuity.

Apr 17

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

CEO Richard Gelfond's temporary medical leave due to pneumonia creates leadership uncertainty and may delay strategic decisions, potentially pressuring IMAX stock until his return timeline clarifies.

Mar 30

8-K

Imax Corp -- 8-K Filing

IMAX projects record $1.4 billion global box office in 2026 with 12+ filmed-for-IMAX releases, signaling strong theatrical demand and expanding market share opportunities for investors.

Feb 25

Data updated apr 25, 2026 3:15pm · Source: massive.com